论文部分内容阅读
肝细胞肝癌(HCC)为源自于乙型肝炎病毒与丙型肝炎病毒感染背景、化学毒物摄入或非酒精性脂肪性肝病等慢性炎症。癌变肝细胞可表达和分泌多种相对特异性的标志物，如癌胚型的甲胎蛋白、磷脂酰肌醇蛋白多糖-3、Wnt/β-catenin通路关键信号分子Wnt3a和肝癌特异性GGT-II等，临床分析癌胚型标志物除有助于HCC诊断和预后判别外，也可能是HCC免疫治疗的靶目标，具有开发应用前景。现对有价值的癌胚型特异分子标志物与肝癌免疫治疗的最新进展进行评述。“,”Hepatocellular carcinoma (HCC) is a chronic inflammation derived from the background of hepatitis B and C virus (HBV and HCV) infection, chemical intoxicants, or non-alcoholic fatty liver disease. Cancerous liver cells can express and secrete a variety of relatively specific markers, such as carcinoembryonic type of alpha-fetoprotein (AFP), phosphatidylinositol-3 (Glypican-3, GPC-3), Wnt/β-Catenin key molecule of signaling pathway Wnt3a and liver cancer specific GGT-II (HS-GGT), etc. Clinical analysis of carcinoembryonic markers not only contributes to diagnosis and prognosis of HCC, but may also be the target of HCC immunotherapy with a promising prospect of development and application. This article reviews the latest valuable advances in carcinoembryonic type specific molecular markers and liver cancer immunotherapy.